Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in lower-risk myelodysplastic syndrome with ring-sideroblastic phenotype (MDS-RS)
2020-004899-18Phase 3Active
- Sponsor
- GWT-TUD
- Start
- Jun 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of luspatercept in myelodysplastic syndrome (MDS), sponsored by GWT-TUD. Primary endpoint: RBC-TI rate (IWG 2018 modified criteria). Started Jun 2021; status: active.
02
Drugs
luspatercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-004899-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004899-18.